Web Exclusives

The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL.

During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL.

Identifying the risk factors for infection may allow preventive measures to be taken to protect patients.

Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes.

Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures.

This publication was created together with leading patient advocates who shared their experiences and insights, in the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These patient organizations provide education and support to promote your health and well-being, and help with practical matters, logistics, and financial and legal concerns.

Every person with cancer can benefit from a support system that can help manage the physical and emotional aspects of cancer care, as well as help with daily struggles.

Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future.

A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey.